IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease

Journal of Clinical Investigation

Volumn 125, Issue 8, 2015, Pages 3198-3214

  Baek, Jea Hyun ^a   Zeng, Rui ^a,e   Weinmann Menke, Julia ^b   Valerius, M Todd ^a,c   Wada, Yukihiro ^a   Ajay, Amrendra K ^a   Colonna, Marco ^d   Kelley, Vicki R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 34; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN TYROSINE PHOSPHATASE EPSILON; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, MOUSE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DETERIORATION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE CELL; LANGERHANS CELL; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHRONIC KIDNEY FAILURE; EPITHELIUM CELL; GENETICS; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PRIMARY GRAFT DYSFUNCTION; TRANSGENIC MOUSE;

ACUTE KIDNEY INJURY; ANIMALS; EPITHELIAL CELLS; FEMALE; INTERLEUKINS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MACROPHAGES; MICE; MICE, TRANSGENIC; PRIMARY GRAFT DYSFUNCTION; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84939216025     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81166     Document Type: Article

References (69)

1. Lee S, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317-326.
2. Lech M, et al. Macrophage phenotype controls long-term AKI outcomes - kidney regeneration versus atrophy. J Am Soc Nephrol. 2014;25(2):292-304.
3. Iwata Y, et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol. 2012;188(9):4568-4580.
4. Menke J, et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest. 2009;119(8):2330-2342.
5. Bloom RD, Florquin S, Singer GG, Brennan DC, Kelley VR. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int. 1993;43(5):1000-1009.
6. Lenda DM, Stanley ER, Kelley VR. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J Immunol. 2004;173(7):4744-4754.
7. Menke J, et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol. 2009;20(12):2581-2592.
8. Menke J, Iwata Y, Rabacal WA, Basu R, Stanley ER, Kelley VR. Distinct roles of CSF-1 isoforms in lupus nephritis. J Am Soc Nephrol. 2011;22(10):1821-1833.
9. Guilbert LJ, Stanley ER. Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells. J Cell Biol. 1980;85(1):153-159.
10. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41(3):665-676.
11. Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, Stanley ER. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell. 1982;28(1):71-81.
12. Byrne PV, Guilbert LJ, Stanley ER. Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. J Cell Biol. 1981;91(3):848-853.
13. Wiktor-Jedrzejczak W, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87(12):4828-4832.
14. Dai XM, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99(1):111-120.
15. Wei S, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010;88(3):495-505.
16. Lin H, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807-811.
17. Chihara T, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010;17(12):1917-1927.
18. Wang Y, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13(8):753-760.
19. Nandi S, et al. Receptor-type protein-tyrosine phosphatase zeta is a functional receptor for interleukin-34. J Biol Chem. 2013;288(30):21972-21986.
20. Rubin Kelley V, Bloom RD, Yui MA, Martin C, Price D. Pivotal role of colony stimulating factor-1 in lupus nephritis. Kidney Int Suppl. 1994;45:S83-85.
21. Menke J, et al. Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J Immunol. 2008;181(10):7367-7379.
22. Lenda DM, Kikawada E, Stanley ER, Kelley VR. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol. 2003;170(6):3254-3262.
23. Jang MH, et al. Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation. J Immunol. 2006;177(6):4055-4063.
24. Alikhan MA, et al. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am J Pathol. 2011;179(3):1243-1256.
25. Zhang MZ, et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest. 2012;122(12):4519-4532.
26. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121(11):4210-4221.
27. Bolignano D, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337-344.
28. Hashimoto D, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38(4):792-804.
29. Greter M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity. 2012;37(6):1050-1060.
30. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555.
31. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461.
32. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737.
33. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333(6):333-336.
34. Solary E, Droin N. The emerging specificities of interleukin-34. J Leukoc Biol. 2014;95(1):3-5.
35. Nakamichi Y, Udagawa N, Takahashi N. IL-34 and CSF-1: similarities and differences. J Bone Miner Metab. 2013;31(5):486-495.
36. Zelante T, Ricciardi-Castagnoli P. The yin-yang nature of CSF1R-binding cytokines. Nat Immunol. 2012;13(8):717-719.
37. Masteller EL, Wong BR. Targeting IL-34 in chronic inflammation. Drug Discov Today. 2014;19(8):1212-1216.
38. Dai XM, Zong XH, Sylvestre V, Stanley ER. Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1. Blood. 2004;103(3):1114-1123.
39. Preisser L, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology. 2014;60(6):1879-1890.
40. Peles E, Schlessinger J, Grumet M. Multi-ligand interactions with receptor-like protein tyrosine phosphatase beta: implications for intercellular signaling. Trends Biochem Sci. 1998;23(4):121-124.
41. Li YS, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science. 1990;250(4988):1690-1694.
42. Peles E, et al. The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell. 1995;82(2):251-260.
43. Milev P, et al. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. J Biol Chem. 1998;273(12):6998-7005.
44. Bethunaickan R, Berthier CC, Zhang W, Kretzler M, Davidson A. Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One. 2013;8(10):e77489.
45. Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res. 2009;315(4):602-610.
46. Tang J, Liu N, Zhuang S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int. 2013;83(5):804-810.
47. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest. 1999;103(1):73-80.
48. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318-324.
49. Foucher ED, et al. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and IFNgamma. PLoS One. 2013;8(2):e56045.
50. Swenson-Fields KI, et al. Macrophages promote polycystic kidney disease progression. Kidney Int. 2013;83(5):855-864.
51. Toki D, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14(9):2126-2136.
52. Ikezumi Y, et al. Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury. Pediatr Nephrol. 2015;30(6):1007-1017.
53. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80(9):915-925.
54. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181-194.
55. Li D, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol. 2014;134(6):1422-1432 e1411.
56. Gratchev A, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol. 2001;53(4):386-392.
57. Willment JA, et al. Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol. 2003;171(9):4569-4573.
58. Ryan GR, et al. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood. 2001;98(1):74-84.
59. Baek JH, Birchmeier C, Zenke M, Hieronymus T. The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol. 2012;189(4):1699-1707.
60. Yu J, et al. Identification of molecular compartments and genetic circuitry in the developing mammalian kidney. Development. 2012;139(10):1863-1873.
61. Kobayashi A, et al. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell. 2008;3(2):169-181.
62. Ajay AK, Kim TM, Ramirez-Gonzalez V, Park PJ, Frank DA, Vaidya VS. A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury. J Am Soc Nephrol. 2014;25(1):105-118.
63. Menke J, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007;179(11):7466-7477.
64. Schaldecker T, et al. Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest. 2013;123(12):5298-5309.
65. Vaidya VS, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int. 2011;79(4):464-470.
66. Masuyama J, et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med. 1999;189(6):979-990.
67. Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.
68. Mengel M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12(3):563-570.
69. Haas M, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-283.